Literature DB >> 21784993

Early volume expansion during diarrhea and relative nephroprotection during subsequent hemolytic uremic syndrome.

Christina A Hickey1, T James Beattie, Jennifer Cowieson, Yosuke Miyashita, C Frederic Strife, Juliana C Frem, Johann M Peterson, Lavjay Butani, Deborah P Jones, Peter L Havens, Hiren P Patel, Craig S Wong, Sharon P Andreoli, Robert J Rothbaum, Anne M Beck, Phillip I Tarr.   

Abstract

OBJECTIVES: To determine if interventions during the pre-hemolytic uremic syndrome (HUS) diarrhea phase are associated with maintenance of urine output during HUS.
DESIGN: Prospective observational cohort study. SETTINGS: Eleven pediatric hospitals in the United States and Scotland. PARTICIPANTS: Children younger than 18 years with diarrhea-associated HUS (hematocrit level <30% with smear evidence of intravascular erythrocyte destruction), thrombocytopenia (platelet count <150 × 10³/mm³), and impaired renal function (serum creatinine concentration > upper limit of reference range for age).
INTERVENTIONS: Intravenous fluid was given within the first 4 days of the onset of diarrhea. OUTCOME MEASURE: Presence or absence of oligoanuria (urine output ≤ 0.5 mL/kg/h for >1 day).
RESULTS: The overall oligoanuric rate of the 50 participants was 68%, but was 84% among those who received no intravenous fluids in the first 4 days of illness. The relative risk of oligoanuria when fluids were not given in this interval was 1.6 (95% confidence interval, 1.1-2.4; P = .02). Children with oligoanuric HUS were given less total intravenous fluid (r = -0.32; P = .02) and sodium (r = -0.27; P = .05) in the first 4 days of illness than those without oligoanuria. In multivariable analysis, the most significant covariate was volume infused, but volume and sodium strongly covaried.
CONCLUSIONS: Intravenous volume expansion is an underused intervention that could decrease the frequency of oligoanuric renal failure in patients at risk of HUS.

Entities:  

Mesh:

Year:  2011        PMID: 21784993      PMCID: PMC4064458          DOI: 10.1001/archpediatrics.2011.152

Source DB:  PubMed          Journal:  Arch Pediatr Adolesc Med        ISSN: 1072-4710


  29 in total

1.  von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome.

Authors:  H M Tsai; W L Chandler; R Sarode; R Hoffman; S Jelacic; R L Habeeb; S L Watkins; C S Wong; G D Williams; P I Tarr
Journal:  Pediatr Res       Date:  2001-05       Impact factor: 3.756

2.  The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.

Authors:  C S Wong; S Jelacic; R L Habeeb; S L Watkins; P I Tarr
Journal:  N Engl J Med       Date:  2000-06-29       Impact factor: 91.245

3.  The hemolytic-uremic syndrome.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G E Gallo; E T Sojo
Journal:  Nephron       Date:  1973       Impact factor: 2.847

4.  The hemolytic-uremic syndrome. Renal status of 76 patients at long-term follow-up.

Authors:  C A Gianantonio; M Vitacco; F Mendilaharzu; G Gallo
Journal:  J Pediatr       Date:  1968-06       Impact factor: 4.406

Review 5.  Acute kidney injury: can we improve prognosis?

Authors:  Christine W Hsu; Jordan M Symons
Journal:  Pediatr Nephrol       Date:  2010-04-09       Impact factor: 3.714

Review 6.  [Post-diarrhea hemolytic-uremic syndrome: clinical aspects].

Authors:  C Loirat
Journal:  Arch Pediatr       Date:  2001-09       Impact factor: 1.180

7.  Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome.

Authors:  Wayne L Chandler; Srdjan Jelacic; Daniel R Boster; Marcia A Ciol; Glyn D Williams; Sandra L Watkins; Takashi Igarashi; Phillip I Tarr
Journal:  N Engl J Med       Date:  2002-01-03       Impact factor: 91.245

8.  Recurrent haemolytic uraemic syndrome.

Authors:  M C de Jong; L A Monnens
Journal:  Padiatr Padol       Date:  1976

Review 9.  Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression.

Authors:  Amit X Garg; Rita S Suri; Nick Barrowman; Faisal Rehman; Doug Matsell; M Patricia Rosas-Arellano; Marina Salvadori; R Brian Haynes; William F Clark
Journal:  JAMA       Date:  2003-09-10       Impact factor: 56.272

10.  Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study.

Authors:  Eileen J Klein; Jennifer R Stapp; Carla R Clausen; Daniel R Boster; Joy G Wells; Xuan Qin; David L Swerdlow; Phillip I Tarr
Journal:  J Pediatr       Date:  2002-08       Impact factor: 4.406

View more
  43 in total

1.  Performance of Stool-testing Recommendations for Acute Gastroenteritis When Used to Identify Children With 9 Potential Bacterial Enteropathogens.

Authors:  Gillian A M Tarr; Linda Chui; Bonita E Lee; Xiao-Li Pang; Samina Ali; Alberto Nettel-Aguirre; Otto G Vanderkooi; Byron M Berenger; James Dickinson; Phillip I Tarr; Steven Drews; Judy MacDonald; Kelly Kim; Stephen B Freedman
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

2.  Therapy: Azithromycin and decolonization after HUS.

Authors:  Michael E Seifert; Phillip I Tarr
Journal:  Nat Rev Nephrol       Date:  2012-05-01       Impact factor: 28.314

Review 3.  Shiga Toxin-Producing Escherichia coli Infection, Antibiotics, and Risk of Developing Hemolytic Uremic Syndrome: A Meta-analysis.

Authors:  Stephen B Freedman; Jianling Xie; Madisen S Neufeld; William L Hamilton; Lisa Hartling; Phillip I Tarr; Alberto Nettel-Aguirre; Anderson Chuck; Bonita Lee; David Johnson; Gillian Currie; James Talbot; Jason Jiang; Jim Dickinson; Jim Kellner; Judy MacDonald; Larry Svenson; Linda Chui; Marie Louie; Martin Lavoie; Mohamed Eltorki; Otto Vanderkooi; Raymond Tellier; Samina Ali; Steven Drews; Tim Graham; Xiao-Li Pang
Journal:  Clin Infect Dis       Date:  2016-02-24       Impact factor: 9.079

4.  Atypical reduction of plasma ADAMTS13 activity by a non-IgG-type inhibitor in a patient with hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli.

Authors:  Shinya Nakayama; Shuma Hirashio; Haruka Yorishima; Toshiki Doi; Yoko Yoshida; Masanori Matsumoto; Takao Masaki
Journal:  CEN Case Rep       Date:  2019-06-08

5.  Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children.

Authors:  Alejandro Balestracci; Sandra Mariel Martin; Ismael Toledo; Caupolican Alvarado; Raquel Eva Wainsztein
Journal:  Pediatr Nephrol       Date:  2012-04-03       Impact factor: 3.714

Review 6.  Shiga toxin-producing Escherichia coli O104:H4: an emerging pathogen with enhanced virulence.

Authors:  Dakshina M Jandhyala; Vijay Vanguri; Erik J Boll; Yushuan Lai; Beth A McCormick; John M Leong
Journal:  Infect Dis Clin North Am       Date:  2013-07-24       Impact factor: 5.982

Review 7.  Guidelines for the management and investigation of hemolytic uremic syndrome.

Authors:  Takashi Igarashi; Shuichi Ito; Mayumi Sako; Akihiko Saitoh; Hiroshi Hataya; Masashi Mizuguchi; Tsuneo Morishima; Kenji Ohnishi; Naohisa Kawamura; Hirotsugu Kitayama; Akira Ashida; Shinya Kaname; Hiromichi Taneichi; Julian Tang; Makoto Ohnishi
Journal:  Clin Exp Nephrol       Date:  2014-08       Impact factor: 2.801

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

Review 9.  Recent advances in understanding enteric pathogenic Escherichia coli.

Authors:  Matthew A Croxen; Robyn J Law; Roland Scholz; Kristie M Keeney; Marta Wlodarska; B Brett Finlay
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 10.  Pathogenicity, host responses and implications for management of enterohemorrhagic Escherichia coli O157:H7 infection.

Authors:  Nathan K Ho; Aleah C Henry; Kathene Johnson-Henry; Philip M Sherman
Journal:  Can J Gastroenterol       Date:  2013       Impact factor: 3.522

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.